These medications are long-acting versions of other GLP-1 medications that have been on the market for over a decade such as liraglutide (Victoza, Saxenda), dulaglutide (Trulicity) or exenatide (Byetta, Bydureon)
This is from a recent meta-analysis of seven randomized controlled trials showing tirzepatide did not increase any risk associated with cardiovascular diseases compared to those who are not taking the medication
Another study, the PIONEER 6 trial, found that while semaglutide did not significantly increase the risk of major heart problems, some participants did report palpitations and high blood pressure
The results showed comparable reduction in HbA1c levels, along with similar outcomes across key parameters including Fasting Plasma Glucose (FPG), postprandial glucose (PPG) and weight loss
(Xcel Peptides) PeptideSciences blog, Cellular Senescence: What Can Be Done About It? (FOXO4-DRI category) 2025